JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on KalVista Pharmaceuticals today and set a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Debanjana Chatterjee’s rating is based on the recent FDA approval of KalVista Pharmaceuticals’ new product, Ekterly, for on-demand treatment of hereditary angioedema (HAE). The approval is a significant milestone, and the company has set a competitive launch price for Ekterly, aligning it with existing treatments in the market.
Additionally, KalVista has initiated supportive programs like KalVista Cares and QuickStart to facilitate patient access and engagement, which are expected to drive initial uptake. The strategic focus on key healthcare providers and existing users of similar treatments suggests a well-planned market entry. These factors, combined with the anticipated updates on payer engagement and formulary processes, underpin the Buy rating.
According to TipRanks, Chatterjee is a 4-star analyst with an average return of 13.0% and a 46.88% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Tvardi Therapeutics, KalVista Pharmaceuticals, and Opus Genetics.
In another report released today, Needham also maintained a Buy rating on the stock with a $28.00 price target.